Could growth factors help repair the liver in cirrhosis?

NCT ID NCT07002827

Recruiting now Disease control Sponsor: Institute of Liver and Biliary Sciences, India Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether giving a combination of two growth factors (G-CSF and darbepoetin) in single or repeated cycles can improve immune function in people with early decompensated cirrhosis. Sixty participants will be randomly assigned to receive either the growth factor combination or standard medical care. The main goal is to see changes in immune cell activity over six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Granulocyte colony stimulating factor (G-CSF) and darbepoetin
What this could lead to: If successful, this could point toward a new way to boost the immune system and slow liver disease progression in people with early decompensated cirrhosis.
What could go wrong: This is a small pilot study with only 60 participants, so results may not apply to everyone. The treatment involves growth factors, which can cause side effects like bone pain or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DECOMPENSATED LIVER CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic liver failure cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DECOMPENSATED LIVER CIRRHOSIS

Contacts and locations

Locations

Institute of Liver & Biliary Sciences (ILBS)
RECRUITING

New Delhi, National Capital Territory of Delhi, 110070, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.